Advertisement

Baxter Confirms Receipt of Complete Response Letter on HyQ

16:01 EDT 1 Aug 2012 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Baxter International Inc. (NYSE:BAX) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for HyQ, an investigational combination immunoglobulin product for the treatment of pati...

Other Sources for this Article

Baxter International Inc.
Media Contacts
Deborah Spak, 224-948-2349
Brian Kyhos, 224-948-4210
or
Investor Contacts
Mary Kay Ladone, 224-948-3371
Clare Trachtman, 224-948-3085

NEXT ARTICLE

More From BioPortfolio on "Baxter Confirms Receipt of Complete Response Letter on HyQ"

Search BioPortfolio: